04.06 and 04.07 - Atherosclerosis Flashcards

1
Q

What is atherosclerosis, and its epi?

A
  • Disease of arterial intimal thickening due to lipid accumulation, chronic inflammation, repair response
  • Involves medium (muscular) and large (elastic) aa
  • Coronary atherosclerosis -> MI, cerebral -> cerebral infarction, and leg involvement gangrene
  • Universal prevalence in adults; serious (causes half of deaths; MI ¼ of deaths)
  • Typically middle age (incidence of MI INC 5-fold b/t age 40 and age 60, 10 years earlier in men)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do risk factors affect atherosclerotic CV events?

A
  • 80% of atherosclerotic CV events, like infarctions, occur in ppl with risk factors
  • Major risk factors multiplicative rather than additive
  • Subdivide into “constitutional,” like age and sex, and modifiable, like high chol, HTN, smoking, diabetes, inflammation, high BP, physical inactivity, etc.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

SHODDY

A
  • Smoking
  • HTN
  • Obesity: 2x risk of MI, 100x risk of leg gangrene
  • Diabetes
  • Dyslipidemia: low HDL, high LDL
  • Inflammation also an independent predictor (i.e., high serum C-reactive protein)
  • Physical inactivity also a predictor, but obesity is a stronger independent risk factor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 major concepts of atherosclerosis?

A
  1. Atherosclerosis is a chronic inflammatory disease
  2. Obesity contributes to atherosclerosis partly by being a pro-inflammatory and pro-thrombotic state
  3. Atherosclerosis is a disease of response to endo cell injury
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the 5 steps in the pathogenesis of atherosclerosis?

A
  1. Endo injury and dysfunction -> increased vascular permeability and leukocyte, platelet adhesion to endo
  2. Accumulation of lipoproteins (mainly LDL and its oxidized forms) in the intima
  3. Monocyte migration into intima and transformation into macrophages and foam cells
  4. Factor release from activated platelets, macros, and vascular wall cells -> smooth muscle cell recruitment, from the media, and recruitment of T cells*
  5. Smooth muscle cell proliferation, ECM production

*NOTE: T cells important in later complicated athero

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the dominant lipids in atheromatous plaques?

A

Cholesterol and cholesterol esters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How are plasma cholesterol and LDL implicated?

A
  • Genetic defects in lipoprotein uptake & metabolism that cause hyperlipoproteinemia are associated with accelerated atherosclerosis
    1. Ex: familial hypercholesterolemia - defective LDL receptors and inadequate hepatic LDL uptake can precipitate MI before age 20
  • Other genetic/acquired diseases (e.g., diabetes, hypothyroidism) that cause hyper-cholesterolemia lead to premature atherosclerosis
  • Epi shows significant correlation b/t severity of atherosclerosis and levels of total plasma cholesterol or LDL
  • Lowering serum chol by diet/drugs slows rate of progression of atherosclerosis, causes regression of some plaques, and reduces risk of CV events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the mechanisms by which hyperlipidemia contributes to atherosclerosis?

A
  • Can directly impair endo cell function by increasing local ROS production; besides causing mem & mito damage, oxygen free radicals accelerate NO decay, dampening its vasodilator activity
  • W/chronic hyperlipidemia, lipoproteins accumulate in intima, may aggregate or become oxidized by free radicals produced by inflammatory cells -> modified LDL accumulated by macros through a variety of scavenger receptors (distinct from the LDL receptor)
  • Modified lipoproteins can’t be completely degraded, so chronic ingestion leads to formation of lipid-filled macros, foam cells; smooth muscle cells can transform into foam cells by ingesting modified lipids via LDL-receptor related proteins
  • Modified lipoproteins toxic to endo cells, smooth muscle cells, and macros, and their binding and uptake stimulates release of growth factors, cytokines, chemokines that create a vicious cycle of monocyte recruitment and activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does chronic inflammation contribute to atherosclerosis?

A
  • Triggered by accumulation of cholesterol crystals & FFA in macros & other cells -> contributes to initiation and progression of athero lesions
  • Cells sense abnormal materials via cytosolic innate immune receptors (components of inflammasome); resulting inflammasome activation -> release of pro-inflam IL-1, which recruits leukocytes, incl monocytes
  • T lymphos activated, but what they recognize and why substances detected as foreign invaders unkown
  • Net result of macro, T cell activation local production of cyto/chemokines; recruit, activate more inflam cells
  • Activated macros produce ROS that enhance LDL oxidation, and growth factors driving smooth muscle cell proliferation
  • Activated T cells in the growing intimal lesions elaborate inflam cytokines, e.g., IFN-γ, which, in turn, can activate macros, endo, and smooth muscle cells; leukos and vascular wall cells release growth factors that promote smooth muscle prolif and syn of ECM proteins -> many lesions of athero attributable to the chronic inflammatory reaction in the vessel wall
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How are smooth muscle cells implicated in atherosclerosis?

A
  • Inti­mal smooth muscle cell prolif and ECM deposition convert fatty streak into mature atheroma, contributing to progressive growth of atherosclerotic lesions
  • Intimal sm m cells have prolif, synthetic phenotype distinct from underlying medial smooth muscle cells
  • Implicated growth factors in sm m prolif incl: PDGF, released by locally adherent platelets, macros, endos, and smooth muscle cells, FGF, and TGF-alpha
  • These factors also stimulate smooth muscle cells to synthesize ECM (notably collagen), which stabilizes atherosclerotic plaques
  • In contrast, activated inflam cells in atheromas may increase breakdown of ECM components, resulting in unstable plaques
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the evolution of visible wall changes in the response to injury hypothesis. NOTE: not the same as the 5 steps of pathogenesis.

A
  1. Normal
  2. Endo injury with monocyte and platelet adhesion
  3. Monocyte, smooth muscle cell migration into the intima, with macrophage activation
  4. Macro, smooth muscle uptake of modified lipids, with further activation and recruitment of T cells.
  5. Intimal smooth muscle proliferation with ECM production, forming a well-developed plaque
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why is LDL bad cholesterol?

A
  • After accumulating in tunica intima, LDL modified by being oxidized and glycated -> subsequently trapped in tunica intima
  • Modified LDL not taken up by macros via LDLr, but by a scavenger receptor -> problem is that this has no feedback inhibition and macros take up massive quantities of LDL, becoming dysfunctional foam cells, which die
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the sequence of cellular interactions in atherosclerosis?

A
  • Hyperlipidemia, hyperglycemia, HTN, other things cause endo dysfunction resulting in platelet adhesion and recruitment of circulating monocytes and T cells
  • Subsequent cytokine, growth factor release (IL-1, mono chemoattractant protein-1, IFN-gamma) from inflam cells leads to smooth muscle cell migration and proliferation, & further macro activation
  • Foam cells in atheromatous plaques derive from macros and smooth muscle that have accumulated modified lipids, e.g., oxidized, aggregated LDL via scavenger, LDL-receptor-related proteins
  • EC lipid derived from insudation from vessel lumen, esp in presence of hypercholesterolemia, and from degenerating foam cells
  • Cholesterol plaque accumulation reflects imbalance b/t influx and efflux; HDL likely helps clear cholesterol from these accumulations
  • In response to elaborated cyto/chemokines, smooth muscle cells migrate to intima, proliferate, and make ECM, incl collagen and proteoglycans
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the three principal components of atherosclerotic plaques?

A
  1. Smooth muscle cells, macros, T-cells
  2. ECM, incl collagen, elastic fibers, proteoglycans
  3. IC and EC lipid
    - Note: these components present in varying proportions and configurations in different lesions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does an atherosclerotic plaque contain?

A
  • Typically, a superficial fibrous cap made of smooth muscle and collagen; beneath, to side of the cap (the “shoulder”) is a more cellular area w/macros, T cells, smooth muscle cells
  • Deep to fibrous cap is a necrotic core, with lipid (mainy chol, chol esters), debris from dead cells, foam cells (lipid-laden macrophages, smooth muscle cells), fibrin, variably organized thrombus, and other plasma proteins; chol content frequently present as crystalline aggregates washed out in tissue processing, leaving behind only empty “clefts
  • Periphery of the lesions show neovascularization, or proliferating small blood vessels
  • Most atheromas contain abundant lipid, but some plaques (“fibrous plaques”) are composed almost exclusively of smooth muscle cells and fibrous tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do these images show the progression of atherosclerosis?

A

A. Minimal, but intima > 2 cells thick

B. Mild: some recruited monos have become foam cells, but most lipid is IC

C. Moderate: intima now much thicker than media, and pools of lipid

D. Still moderate, but cap of fibrous tissue over top of lipid (or necrotic core)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What do these stains emphasize?

A
  • Plaques generally continue to change, progressively enlarge through cell death and degeneration, syn and degradation (remodeling) of ECM, and organization of any superimposed thrombus
  • Atheromas often undergo calcification; patients with advanced coronary calcification have increased risk for coronary events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe the eccentricity of atherosclerosis.

A
  • Lesions patchy, usually involve only a portion of any given arterial wall and are rarely circumferential; on cross-section, the lesions therefore appear ‘eccentric’
  • Focality of atherosclerotic lesions, despite uniform exposure of vessel walls factors like cigarette smoke toxins, elevated LDL, and hyperglycemia attributable to vagaries of vascular hemodynamics
  • Local flow disturbances, like turbulence at branch points, make certain portions of a vessel wall more susceptible to plaque formation
  • Although focal and sparsely distributed at first, with time atherosclerotic lesions can become larger, more numerous, and more broadly distributed -> in any given vessel, lesions at various stages often coexist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How is neovascularization implicated in atherosclerosis?

A
  • Feature of later athero
  • Ingrowth of capillaries through tunica adventitia and tunica media to cells in massively thickened tunica intima, demanding vasa vasorum in an artery normally not needing them b/c oxygen, nutrients can normally get to few cells in the tunica intima by diffusion from the lumen
  • These abnormal, irregular small blood vessels are prone to rupture
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What does the timeline of athero devo usually look like?

A
  • First decade: clinically silent, and growth mainly via lipid accumulation
    1. Initial lesion: histo normal, macro infiltration, isolated foam cells
    2. Fatty streak: mainly IC lipid accumulation
  • Third decade: clinically silent, and growth mainly via lipid accumulation
    1. Intermediate lesion: IC lipid accumulation, small EC lipid pools
    2. Atheroma: IC lipid buildup, core of ECM lipid
  • Fourth decade: clinically silent or overt, increased sm m and collagen, thrombosis and/or hematoma
    1. Fibroatheroma: single or multiple lipid cores, fibrotic/calcific layers
    2. Complicated lesion: surface defect, hematoma, hemorrhage, thrombosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the role of physical disruption (i.e., rupture) of coronary arterial plaques in fatal coronary events.

A
  • Frank rupture of fibrous cap in vulnerable plaque and superficial erosion of coronary artery may cause death
  • Fibrous cap typically overlies lipid-rich center of an atheromatous plaque, standing b/t blood, with latent coag factors, and lipid core, a portion of the plaque filled with thrombogenic material
  • Plaques that have ruptured and caused fatal MI often, but not always, have thin fibrous caps; ruptured plaques also tend to have large lipid cores, abundant inflam cells, and punctate or spotty calcification
  • > 30% of these plaques associated with a luminal stenosis of less than 75%
22
Q

How does superficial erosion of coronary atheromata cause fatal acute MI?

A
  • Causes 20-25% of cases of fatal acute MI, more in F
  • Many lack prominent inflam infiltrates and exhibit proteoglycan accumulation
  • Apoptosis of endo cells -> desquamation; oxidative stress can promote endothelial apoptosis
  • Hypochlorous acid (product of MPO released by activated leukocytes) can initiate endo cell apoptosis
  • As these cells undergo apoptosis, they produce the procoagulant tissue factor
  • Modified LDL can induce MMP-14 via endo cells, and activate MMP-2 that degrades type IV collagen
23
Q

What is Lp-PLA2?

A
  • Circulating level of this enzyme is an independent predictor of CV events
  • Lipoprotein-associated phospholipase A2, produced by inflam cells, travels with circulating LDL, and hydrolyzes oxidized phospholipids in LDL
  • Pro-inflammatory role mediated by products of the Lp-PLA2 reaction (lysophosphatidylcholine and oxidized nonesterified fatty acids) generated in atherosclerotic lesions -> bioactive lipids up-regulate MCP-1 (monocyte chemoattractant protein-1), ICAM-1 and VCAM-1 on endo cells, making them vasodilate less in response to NO and undergo apoptosis
  • Also upregulate expression of MCP-1 on macros, making them secrete IL-1beta and undergo apoptosis
24
Q

What are the critical points in the pathology of atherosclerosis?

A
  1. Vulnerable plaque has displaced luminal stenosis as critical determinant of ischemia, infarction and death (events) due to atherosclerosis (AS)
  2. Determinants of vulnerability are: (A) thinness of the fibrous cap, (B) size of lipid (necrotic) core, (C) amt of inflammation, and (D) amt of calcification
  3. Up to 75%* of AS events due to plaque rupture
  4. Up to 25%* of AS events are from plaque erosion
  5. Although atherosclerosis is a chronic inflammatory disease, events from it are most commonly due to thrombosis superimposed on it

***Don’t ignore the “up to;” there are other causes

25
Q

What do you see here?

A
  • Acute plaque rupture, left anterior descending coronary artery
  • Acute occlusive thrombus overlying atheroma with rupture on shoulder, and communication of thrombus with atheroma core
26
Q

What is going on here? What are the arrows pointing to?

A
  • RIght coronary artery with coronary thrombosis from ruptured plaque
  • Arrows point to lymphos in adventitia on edge of calcification in ruptured atherosclerotic plaque
  • NOTE: coronary artery thrombosis is demonstrated by angiography w/in 4 hours of onset of MI in almost 90% of cases; angiography is an imaging technique used to view the inside (lumen) of blood vessels
27
Q

What is the difference between these two arteries?

A
  • Left: vulnerable plaque (thin fibrous cap, high lipid content -> risk of intraplaque hemorrhage, rupture, and superimposed thrombosis)
  • Right: stable plaque
28
Q

What is the treatment for prevention of atherosclerotic thrombotic events?

A
  • Low-dose aspirin therapy has clearly and consistently shown substantial net benefit for persons at high risk for subsequent events secondary to existing CV disease -> those with previous MI, stroke, bypass sx, peripheral vascular surgery, or angina
  • HOWEVER, most data on ASA in primary prevention predate concomitant use of statin therapy; with medical therapy instituted as an adjunct to diet, exercise, and smoking cessation, many cardiologists considering such therapy now begin with a statin rather than aspirin in primary prevention
29
Q

How does statin therapy work?

A
  • Lipid lowering can INC the fibrous nature of plaques, a change that should confer resistance to rupture
  • Imaging studies suggest plaques have more fibrous character in pts receiving treatment with statins
  • Stabilizing effect on plaques that extends beyond lipid lowering -> assoc w/reduced lipid content and indexes of macro activity, and more fibrous atheromas
  • Statin tx has prevented acute coronary syndromes in broad categories of pts, even though interventions have little effect on degree of stenosis as assessed on angiography and result in only modest reductions in atheroma volume as assessed on IV ultrasonography
30
Q

Who is statin therapy recommended for?

A
  • Pts > 21 y/o with clinical atherosclerotic CV disease
  • Pts > 21 y/o with LDL-cholesterol > 190 mg/dl
  • Patients > 39 y/o with diabetes
  • Pts > 39 y/o w/estimated >7.5% risk of atherosclerotic CV disease over the next 10 years
  • Note: this was a recommendation for millions more patients to take statin therapy than were on statin therapy at the time the guideline was issued
31
Q

Compare the efficacy of statin tx to that of revascularization procedures.

A
  • Revascularization procedures that target occlusive coronary stenosis have not consistently reduced the risk of an acute coronary syndrome or death from coronary artery disease
  • Contemporary medical therapy - notably, statin tx - has prevented both first and recurrent acute coronary syndromes in broad categories of patients
32
Q

What are the probable mechanisms by which lipid lowering improves atherosclerosis and prevents thrombotic complications (8)?

A
  • Reduces inflammation (lowers levels of macros, chemo and cytokines, and expression of leukocyte adhesion molecules)
  • Reduces expression of interstitial collagenase (MMP1)
  • Increases levels of interstitial collagen
  • Lowers levels of oxidized LDL
  • Reduces production of ROS
  • Increases expression of endo NO synthetase
  • Reduces thrombotic potential (reduced tissue factor content and activity)
  • Increases fibrinolytic potential (reduced level of plasminogen activator inhibitor-1)
33
Q

How are T-cells implicated in atherosclerotic plaque instability?

A
  • Exposure to IFN-gamma released by activated T-cells strongly inhibits ability of smooth muscle cells to __make new collagen required to repair, maintain integrity of fibrous cap
  • Even in smooth-muscle cells maximally stimulated with TGF-β to produce interstitial collagen
  • Inverse correlation b/t T-cell accumulation in atherosclerotic plaques and mRNA that encodes precursor of interstitial collagen -> inhibition of new collagen synthesis by a T-cell–derived mediator
34
Q

How are macrophages implicated in atherosclerotic plaque instability?

A
  • Interstitial collagen usually very stable and resists degradation by most proteolytic enzymes -> only a handful of human proteinases have interstitial collagenase activity capable of catalyzing the initial attack on fibrillar collagen
  • Macros __overproduce all three human MMP interstitial collagenases - MMP-1, MMP-8, and MMP-13 - in plaques (macros abound in lesions that have caused fatal thrombi)
35
Q

Why is macro-T-cell cross-talk a factor in the instability of atherosclerotic plaques?

A
  • Plaques similar to those that have caused thrombotic complications have biochem signatures of collagen cleavage in situ in macro-rich regions
  • Studies of regulation of macro MMP production have shown that T-cell–derived cytokine CD40 ligand (CD154) boosts production of interstitial collagenase by macros
  • Cross-talk b/t adaptive immune cells (T cells) and more numerous innate immune effector cells (macros) inhibits synthesis (IFN-gamma) & augments degradation (MMPs) of interstitial collagen
36
Q

What are the most extensively involved vessels in atherosclerosis?

A
  • Most extensively involved vessels:
    1. Lower abdominal aorta (abdominal aorta typically involved to a much greater degree than thoracic aorta)
    2. Coronary arteries (first to be clinically manifest is often coronary disease)
    3. Popliteal arteries
    4. Internal carotid arteries (aka, cerebral)
    5. Vessels of the circle of Willis
  • Vessels of upper extremities, mesenteric and renal arteries usually spared, except at ostia (opening)
  • Although most individuals have consistent degree of atherosclerotic burden in affected vasculature, severity of disease in one arterial distribution does not always predict its severity in another
  • Important to know bc it determines what organs are involved and how atherosclerosis presents
37
Q

Where do acute coronary disease events usually manifest?

A
  • 1/2 in LAD
  • 1/3 in RCA
  • 1/6 in LCX
38
Q

What clinically important pathologic changes are atherosclerotic plaques susceptible to?

A
  • Acute changes can cause ischemia, infarction or death (or no symptoms at all)
  • Susceptible to:
    1. Rupture
    2. Ulceration
    3. Erosion
  • Exposes highly thrombogenic substances, leads to thrombosis -> may partially or completely occlude vessel lumen; If pt survives, clot may organize and incorporate into growing plaque
39
Q

What is intraplaque hemorrhage?

A
  • Atherosclerotic plaques susceptible to hemorrhage into a plaque
  • Rupture of overlying fibrous cap, or of thin-walled vessels in areas of neovascularization, can cause intraplaque hemorrhage [that] may expand the plaque or induce plaque rupture
40
Q

What makes diagnosis of atheroembolism evident?

A
  • Usually the cholesterol clefts
  • Atherosclerotic plaques susceptible to atheroembolism
  • Plaque rupture can discharge atherosclerotic debris into bloodstream, producing microemboli
41
Q

What is atherosclerotic stenosis?

A
  • Early stages: remodeling of artery, expanding it outward (dilating it) to preserve lumen size (angiography showing only lumen will fail to reveal this form of disease)
  • Limits on extent of remodeling, and expanding atheroma eventually impinges on lumen to such a degree that blood flow is compromised
  • Critical stenosis: stage when occlusion sufficiently severe to produce tissue ischemia; typically 70% decrease in luminal cross-sectional area
    1. 70% coronary stenosis = angina (chest pain due to myocardial ischemia) may devo with exertion; chest pain w/fixed amt of exertion, stable angina
    2. Effects of vascular occlusion depend on metabolic demand of affected tissue and arterial supply
42
Q

What are 4 examples of atherosclerosis leading to diminished arterial perfusion?

A
  1. Flow-limiting mesenteric stenosis can cause bowel ischemia
  2. Coronary stenosis can cause chronic ischemic heart disease or sudden cardiac death
  3. Cerebrovascular stenosis can cause ischemic encephalopathy
  4. Lower aortic, iliac or femoral stenosis can cause intermittent claudication (leg pain with exertion)
43
Q

What is acute plaque change?

A
  • Plaque erosion or rupture typically goes on to partial or complete vascular thrombosis, resulting in acute tissue infarction
  • Three general categories:
    1. Rupture, releasing highly thrombogenic plaque constituents into the bloodstream
    2. Erosion, exposing thrombogenic subendothelial basement membrane to blood
    3. Hemorrhage into the atheroma, expanding its volume (terms fissuring and ulceration sometimes used, but are ambiguous b/t rupture and erosion)
  • Plaques responsible for acute coronary syndromes often asymptomatic before acute change
  • Majority of plaques that undergo abrupt disruption and coronary occlusion had only mild to moderate noncritical luminal stenosis before acute change -> large # of now asymptomatic adults may be at risk for catastrophic coronary event
  • Presently impossible to identify such individuals, part of what makes primary prevention (prophylaxis) so critical
44
Q

What kinds of things contribute to plaque disruption?

A
  • Plaques rupture when unable to withstand mechanical stresses generated by vascular shear forces -> include both intrinsic (plaque structure and composition) and extrinsic elements (BP, platelet reactivity, vessel spasm)
  • SYM stimulation can INC systemic BP or induce local vasoconstriction, INC physical stresses -> SYM activity associated w/waking can cause BP spikes (followed by INC platelet reactivity) that have been causally linked to pronounced circadian periodicity for onset of acute MI (peaking between 6 am and noon)
  • Intense emotional stress can also contribute to plaque disruption (uptick in the incidence of sudden death assoc with natural or other disasters)
45
Q

Do all plaque ruptures result in occlusive thromboses?

A
  • NO: plaque disruption and ensuing superficial platelet aggregation & thrombosis probably common, repetitive, and often clinically silent complications of atheroma
  • Healing of these subclinical plaque disruptions, and resorption of their overlying thrombi, is an important mechanism in the growth of atherosclerotic lesion
46
Q

What kinds of complications of atherosclerosis cause coronary syndromes?

A
  • Partial or total thrombosis superimposed on disrupted plaque is a central factor in acute coronary syndromes
  • In its most serious form, thrombosis leads to total occlusion of affected vessel, causing myocardial ischemia leading to infarction if unrelieved
  • In other coronary syndromes, luminal obstruction by the thrombus incomplete, and may wax and wane with time depending on whether coagulation or fibrinolysis “winning”
47
Q

What are these?

A
  • Microemboli
  • Thrombi in coronary artery can embolize
  • Small embolic fragments of thrombus can often be in the distal intramyocardial circulation or in association with microinfarcts in pts with atherosclerosis who die suddenly
48
Q

What 4 factors may stimulate vasoconstriction at sites of atheroma?

A
  • Vasoconstriction compromises lumen size, and, by INC local mechanical forces, can potentiate plaque disruption
  • May be stimulated at sites of atheroma by:
    1. Circulating adrenergic agonists
    2. Locally released platelet contents
    3. Endo cell dysfunction with impaired secretion of endothelial-derived relaxing factors (NO) relative to contracting factors (endothelin)
    4. Mediators released from perivascular inflam cells
49
Q

What do you think happened here?

A
  • MI with sudden death in a woman in her 20s attributable to repeated coronary vasospasm from cocaine
  • Intramyocardial coronary angiopathy in this case
  • Luminal stenosis from smooth muscle cell hypertrophy, and degeneration -> manifested by vacuolization of the cytoplasm
50
Q

Know this.

A

Good job!